Immunologic Features in De Novo and Recurrent Glioblastoma Are Associated with Survival Outcomes

• Published in: Cancer immunology research 2022-07, Vol.10 (7), p.800-810
• Main Authors: Alanio, Cécile, Binder, Zev A, Chang, Renee B, Nasrallah, MacLean P, Delman, Devora, Li, Joey H, Tang, Oliver Y, Zhang, Logan Y, Zhang, Jiasi Vicky, Wherry, E John, O'Rourke, Donald M, Beatty, Gregory L
• Format: Article
• Language: English
• Subjects: Brain Neoplasms - genetics; Chemoradiotherapy; Glioblastoma - genetics; Humans; Neoplasm Recurrence, Local - pathology; Prognosis
• ISSN: 2326-6066; 2326-6074
• DOI: 10.1158/2326-6066.CIR-21-1050

Glioblastoma (GBM) is an immunologically "cold" tumor characterized by poor responsiveness to immunotherapy. Standard of care for GBM is surgical resection followed by chemoradiotherapy and maintenance chemotherapy. However, tumor recurrence is the norm, and recurring tumors are found frequently to have acquired molecular changes (e.g., mutations) that may influence their immunobiology. Here, we compared the immune contexture of de novo GBM and recurrent GBM (rGBM) using high-dimensional cytometry and multiplex IHC. Although myeloid and T cells were similarly abundant in de novo and rGBM, their spatial organization within tumors differed and was linked to outcomes. In rGBM, T cells were enriched and activated in perivascular regions and clustered with activated macrophages and fewer regulatory T cells. Moreover, a higher expression of phosphorylated STAT1 by T cells in these regions at recurrence was associated with a favorable prognosis. Together, our data identify differences in the immunobiology of de novo GBM and rGBM and identify perivascular T cells as potential therapeutic targets. See related Spotlight by Bayik et al., p. 787.